London, United Kingdom
Sable Bio, founded in 2023, is a UK-based innovator at the nexus of AI, Biotechnology, and Privacy and Security. The company is committed to transforming drug development with its pioneering approach to predicting drug safety, thereby minimizing trial failures and optimizing patient outcomes. Their tagline, "Empowering Discovery: Precision Insights for Safer Drug Targets," encapsulates their mission to provide precision insights that enhance the drug development process.
With a recent €10.00M seed investment secured on 14 April 2026 from notable investors such as BoxGroup, Redalpine, Frst, Gradient, Aidan Gomez, Clement Delangue, and Mario Goetze, Sable Bio is positioned for impactful growth. Its data-driven methodology in assessing clinical side effects emphasizes enhanced validation strategies and risk reduction. This financial backing underscores investor confidence in Sable Bio's innovative capabilities and potential to reshape the biotech industry.
